Medication Adherence Expertise Center Of the northern Netherlands (MAECON)

November 18, 2019



When?: The story



Who? (1): Faculty members

- Job van Boven (coordinator) drug utilization, health economics
- Liset van Dijk (coordinator) sociology, health services
- Paul Brand education, pediatrics
- Petra Denig drug utilization, pharmacoepidemiology
- Paul Hagedoorn (inhaler)technology
- Eelko Hak *big data, pharmacoepidemiology*
- Janwillem Kocks general practice, questionnaires
- Jasper Stevens pharmacometrics, PK/PD modeling
- Katja Taxis elderly medicine, low income solutions
- Daan Touw biochemical measurement
- Marcia Vervloet health communication
- Hans Wouters health psychology

| | rijkansiversitat gronizen | umcs |
|---------------------|------------------------------|----------|
| THE REAL OF ALL AND | SST SHOTABIL | Web. Ab. |

Who? (2): Steering committee

- Role: Visibility & input
- Prof. Jos Kosterink, clinical pharmacy & pharmacology
- Prof. Hendrika Bootsma, rheumatology
- Prof. Huib Kerstjens, pulmonology
- Prof. Stefan Berger, nephrology
- Prof. Stephan Bakker, nephrology
- Prof. Rijk Gans, internal medicine
- Prof. Dirk-Jan van Veldhuisen, cardiology
- Prof. Jourik Gietema/Hilde Jalving, oncology
- Prof. Sytze Zuidema, elderly care





What?: Medication adherence expertise

Why?: Impact of non-adherence

Real-world:


- EU annually: 200,000 deaths
- €125 billion potentially preventable costs (e.g. hospitalizations, unnecessary step-up to less safe and/or more costly second line drugs)

• Clinical trials:


6

- 10–12% does not take their medication while on treatment
- After one year, almost 40% of trial participants have stopped taking their medication
- 1% adherence increase: \$336,000 cost gain (phase III) due to smaller sample size required





How? (2): Our strategy



Who?(3): MAECON's open ecosystem: working together for making change



Now: Let's kick-off!

